[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Yang ZHANG\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":79},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100602105","long-term-evaluation-of-gestational-endocrine--metabolic-dynamics-100602105",false,"NCT07119177","Long-term Evaluation of Gestational Endocrine & Metabolic Dynamics","Long-Term Effects of Gestational Diabetes Mellitus on Postpartum Chronic Non-Communicable Diseases: A Prospective Cohort Study","LEGEND","Inclusion Criteria:\n\n* Adult patients (≥18 years old) who registered for antenatal care and delivered at Peking University Firest Hospital's obstetrics department between 2007 and 2016.\n* Diagnosed with gestational diabetes mellitus (GDM) during pregnancy via an oral glucose tolerance test (OGTT).\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Lack of pregnancy-related obstetric follow-up records.\n* Inability to cooperate with and complete subsequent scheduled follow-ups.","FEMALE","18 Years",{"count":20,"type":21},800,"ESTIMATED","OBSERVATIONAL","Gestational diabetes mellitus (GDM) is the most common complication and metabolic disorder during pregnancy, with clear risks to both the mother and fetus. In recent years, the long-term chronic diseases and poor prognosis in GDM women after delivery, as well as the risk of obesity and metabolic disorders in their offspring, have become key research topics. However, due to the long duration of GDM's impact on both the mother and offspring and its involvement in multiple disciplines, high-quality cohort studies are scarce. As a result, there is no definitive conclusion regarding the high-risk factors, natural progression, key mediators, timing of interventions, and targets for GDM's long-term effects on mothers and their offspring. This project intends to initiate a prospective follow-up study, establish a specialized cohort for the long-term effects of GDM on both mothers and their offspring, and complete the characterization of the natural course of non-communicable chronic diseases (NCDs) in GDM women and their offspring. The study will also explore high-risk and mediator factors, and develop predictive models. The goal is to provide education, postpartum follow-up, monitoring, and possibly initiate primary prevention for GDM women to reduce the long-term NCD risks, ultimately improving their life expectancy and providing a theoretical basis for intervention.\n\nInclusion Criteria:\n\n1. Adult patients (≥18 years old) who registered for antenatal care and delivered at Peking University Firest Hospital's obstetrics department between 2007 and 2016.\n2. Diagnosed with gestational diabetes mellitus (GDM) during pregnancy via an oral glucose tolerance test (OGTT).\n3. Signed informed consent.\n\nExclusion Criteria:\n\n1. Lack of pregnancy-related obstetric follow-up records.\n2. Inability to cooperate with and complete subsequent scheduled follow-ups.",[25,26],"Gestational Diabetes Mellitus (GDM)","Non-communicable Chronic Diseases",[28,29,26,30,31],"Gestational Diabetes Mellitus","Long-term Impact","Prospective Cohort","Predictive Model","RECRUITING","2025-08-05",{"date":35,"type":36},"2025-08-12","ACTUAL",{"date":38,"type":36},"2025-03-29",{"date":40,"type":21},"2026-12-31",{"name":42,"class":43},"Yang ZHANG","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":44},"100566340","phase-4-levothyroxine-intervention-in-pregnant-women-with-tsh-25-miul-upper-limit-of-reference-range-and-negative-thyroid-peroxidase-antibody-100566340","NCT06653907","Levothyroxine Intervention in Pregnant Women with TSH （2.5 MIU\u002FL-upper Limit of Reference Range） and Negative Thyroid Peroxidase Antibody","Randomized Control Study of Levothyroxine Intervention in Pregnant Women with Thyroid Stimulating Hormone Between 2.5 MIU\u002FL and Upper Limit of Reference Range and Negative Thyroid Peroxidase Antibody","LIGHT","Inclusion Criteria:\n\n1. Women of childbearing age（18-45 years old）, natural pregnancy, singleton pregnancy.\n2. Measure thyroid related indexes within 8 weeks of pregnancy: TSH 2.5mIU\u002FL-ULRR, FT4 is normal and TPOAb negativity.\n3. Willing to sign an informed consent form.\n\nExclusion Criteria:\n\n1. History of recurrent miscarriage (≥3 times).\n2. Assisted reproduction (artificial insemination, in vitro fertilization and embryo transfer);\n3. Suffer from diseases that seriously affect pregnancy outcome, including hypertension, diabetes, heart disease, liver and kidney dysfunction, etc.\n4. Failure of vital organs.\n5. Except autoimmune thyroid disease，suffer from other autoimmune diseases.\n6. Thyroid diseases (including hyperthyroidism, thyroid cancer, thyroid amyloidosis and other extensive intrathyroidal diseases, current subacute thyroiditis, iodine-deficiency endemic goiter, thyroidectomy or 131I treatment, previous thyroid Ultrasound prompts diffuse thyroid disease, etc.).\n7. Use of thyroid-related drugs (lithium carbonate, thioureas, sulfonamides, sodium para-amino salicylate, potassium perchlorate, phenylbutazone, sulfate, tyrosine kinase inhibitor, etc.) during screening and affect thyroid Functional testing drugs. (Including glucocorticoids, metoclopramide, propranolol, amiodarone, sodium valproate, etc.)\n8. Secondary hypothyroidism or central hypothyroidism. (Including pituitary tumors, surgery, radiotherapy, lymphocytic hypophysitis, etc.)\n9. L-T4 allergy.\n10. Unwilling to sign an informed consent.\n11. Other clinicians judged that they are not suitable to participate in the study.","45 Years",{"count":55,"type":21},400,"INTERVENTIONAL",[58],"PHASE4","The goal of this clinical trial is to learn if levothyroxine (L-T4) works to treat pregnant women with TSH 2.5 mIU\u002FL-the upper limit of reference range (ULRR) of pregnancy and TPOAb-negative. It will also learn about the safety of L-T4. The main quesitons the investigator want to answer are:\n\n* Will L-T4 reduce miscarriage rates and have an impact on pregnancy complications in pregnant participants?\n* What medical issues do participants have when taking L-T4 during pregnancy? -Investigators will compare L-T4 with placebo (a substance with a similar appearance without medication) to see if L-T4 could reduce miscarriage rates\n\nParticipants should:\n\n* Take L-T4 or placebo during the whole pregnancy.\n* Visit the hospital once every 6-8 weeks during pregnancy for checkups and tests\n* Keep a diary of their pregncny complications and daily record of L-T4 or placebo intake.\n* Visit the hospital for examination 42 days postpartum for checkups and follow up by phone at 6 and 12 months postpartum.",[61,62,63],"Thyroid Abnormalities","Pregnant Woman","Pregnancy Outcomes",[65,66,67,68,69],"TSH","TPOAb","pregnant women","levothyroxine","outcome","NOT_YET_RECRUITING","2024-10-21",{"date":73,"type":36},"2024-10-23",{"date":75,"type":21},"2024-10-25",{"date":77,"type":21},"2027-10-31",{"name":42,"class":43},""]